Jefferies assumed coverage of Guardant Health with a Buy rating and $32 price target. The firm believes “durable growth stories” in the life sciences and diagnostic tools group with operating leverage, healthy free cash flow and balance sheet optionality “should be rewarded.” The analyst sees a host of headwinds for growth tools and awaits more visibility, and is upbeat on the secular growth drivers in the diagnostics space. Recent survey works points to muted next generation sequencing and proteomics budgets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Enhances Executive Severance and Vesting Provisions
- Guardant Health management to meet with BTIG
- Craig-Hallum would be buyers of Exact Sciences amid weakness
- FDA AdCom recommends approval of Guardant Health’s Shield blood test
- Guardant Health stock halted ahead of FDA review of Shield PMA